Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
2007-02-09
2011-10-04
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
C514S754000, C514S684000
Reexamination Certificate
active
08030359
ABSTRACT:
A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol.
REFERENCES:
patent: 6627767 (2003-09-01), Liu et al.
patent: 2002/0103225 (2002-08-01), Curatolo et al.
patent: 2003/0072801 (2003-04-01), Curatolo et al.
patent: 2003/0104063 (2003-06-01), Babcock et al.
patent: 2003/0185893 (2003-10-01), Beyerinck et al.
patent: 2004/0225018 (2004-11-01), Sunami et al.
patent: 2005/0059810 (2005-03-01), Maeda et al.
patent: 2006/0040999 (2006-02-01), Ali et al.
patent: 2007/0243257 (2007-10-01), Bedos et al.
patent: 7254 (2006-01-01), None
patent: WO03/064376 (2003-07-01), None
patent: WO2004/092136 (2004-10-01), None
patent: WO 2007/005572 (2005-06-01), None
patent: WO 2006/014357 (2006-02-01), None
patent: WO 2007/005572 (2007-01-01), None
patent: WO 2007/067593 (2007-06-01), None
Nan-Horng Lin et al. “Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel farnesyltransferase inhibitor”; Bioorganic & Medicinal Chemistry Letters, Pergamon, Elsevier Science, GB; vol. 14, No. 20, Oct. 18, 2004 pp. 5057-5062 XP004565431; Compounds 20, 21.
Geers Sarah
Lowinger Michael
McKelvey Craig A.
Meyer Robert F.
Zhang Dina
Daniel Mark R.
Fitch Catherine D.
Ivanova Svetlana M
McGinnis James L.
Merck Sharp & Dohme Corp.
LandOfFree
Polymer formulations of CETP inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymer formulations of CETP inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymer formulations of CETP inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4287862